On this page
What should the Module 5 clinical reference package include?
Provide the identifiable documents supporting the relevant clinical citations, including important publications and applicable official advice or meeting records. Check their actual versions, content and context. Distinguish a reference used for background from published evidence serving a more specific efficacy or safety report role.
Before you begin
Clinical reference material in 5.4. Publications serving as primary clinical evidence may require report-family placement as well as precise cross-references.
What you will prepare: A deduplicated reference package with verified identity, accurate citations and visible evidence limitations.
Collect the documents behind the citations
Export references from the Clinical Overview, Clinical Summary and relevant technical reports, then obtain the actual cited versions. M4E's reference section includes important publications and relevant official advice or meeting records; it is not limited to journal articles. Record title, authors or issuing body, date, identifier and the dossier locations that cite it.
Distinguish a bibliographic record from an available document. A DOI, abstract or working hyperlink does not prove the complete source is in the package. If only an abstract is available, label that limitation and ask the scientific owner whether it supports the intended claim. Do not expand an abstract into a fabricated full study report.
Check what the source actually supports
Read the relevant passage together with the population, product, endpoint and study limitations. Record corrections or retractions where identified, and determine whether the cited version remains the appropriate evidence. For agency advice, preserve the actual application context and status; a meeting discussion is not automatically an approval or a universal rule.
If a publication provides important evidence for the claimed efficacy rather than background context, assess the appropriate 5.3.5 report-family treatment with the regulatory owner. Avoid a blanket rule that every published paper belongs only in 5.4. Use one authoritative copy where appropriate and precise cross-references rather than independently maintained duplicates.
Verify the citation-to-file path
Fictional exercise: the clinical summary cites a final article, but the supplied file is an earlier conference abstract with a shorter follow-up period. Compare identity and results, obtain the intended article or qualify the claim to the available source. Renaming the abstract with the article's title does not resolve the evidence gap.
Use consistent document titles and inspect legibility, page completeness and reference links in the assembled package. Resolve duplicate records that have different spellings or identifiers. The final handoff should let a reviewer move from a material clinical assertion to the exact supporting document without guessing which version was intended.
Assign each reference a role before checking its filename
Use the following record to make source identity and clinical relevance separate review questions.
| Role | Record | Qualification to preserve |
|---|---|---|
| Background | Cited statement and exact source passage | Context is not direct evidence for this product |
| Clinical evidence | Population, product, outcome and follow-up | Applicability and reporting limitations |
| Regulatory advice | Issuer, date, application context and status | Advice is not automatically approval or a universal rule |
| Updated publication | Earlier version, correction and affected claims | Which evidence changed and which remains valid |
Review exercise: an official meeting record is cited as if it approved the final study design, but the discussion concerned an earlier proposal. Retain the actual record and ask the regulatory owner to resolve the extent of the advice. Do not improve the apparent support by paraphrasing away the qualification.
Check the final citation-to-file path from the clinical overview and the clinical summary reference inventory. One authoritative source copy can support several precise references without becoming several independent pieces of evidence.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is section 5.4 limited to journal articles?
No. M4E includes referenced documents such as important publications, official meeting minutes and other relevant regulatory guidance or advice. Identify the actual document and its context so reviewers can assess what the citation supports.
Can an abstract be supplied under the title of the final article?
No. An abstract and final article can differ in methods, follow-up and results. Identify the document actually available and obtain the intended source or qualify the claim. Renaming the file cannot resolve an evidence-version mismatch.
Does all published clinical evidence belong only in the literature section?
No. A publication important to the efficacy demonstration may need treatment in the appropriate clinical report family under M4E. Assess its role and use precise cross-references rather than assuming publication format alone determines its only location.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.4. A heading identifies placement, not mandatory applicability.